Actos, Glustin(pioglitazone)
/ Pioglitazone, Actoplus Met, Actos, Competact, Duetact, Incresync, Oseni, Pioglitazone, Tandemact (pioglitazone) is a small molecule pharmaceutical. Pioglitazone was first approved as Actos on 1999-07-15. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma. In addition, it is known to target transient receptor potential cation channel subfamily M member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Actos (generic drugs available since 2012-10-26)
CombinationsActoplus met, Duetact, Oseni (generic drugs available since 2012-10-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alogliptin benzoate
+
Pioglitazone hydrochloride
Glimepiride
+
Pioglitazone hydrochloride
Metformin hydrochloride
+
Pioglitazone hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alogliptin and pioglitazone | NDA authorized generic | 2022-09-20 |
| duetact | New Drug Application | 2022-10-24 |
| oseni | New Drug Application | 2023-12-04 |
| pioglitazone and glimepiride | NDA authorized generic | 2021-12-16 |
| pioglitazone hydrochloride and glimepiride | ANDA | 2018-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Alogliptin Benzoate / Pioglitazone Hydrochloride, Oseni, Takeda Pharms Usa | |||
| 8637079 | 2029-06-04 | DP | |
| 7807689 | 2028-06-27 | DS, DP | U-1337 |
| 8173663 | 2025-03-15 | U-1338 | |
| 8288539 | 2025-03-15 | DP | |
| Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
| 9320714 | 2029-02-03 | DP | |
| 9101660 | 2027-01-22 | DP | |
| Glimepiride / Pioglitazone Hydrochloride, Duetact, Takeda Pharms Usa | |||
| 8071130 | 2028-06-08 | DP | |
| 7700128 | 2027-01-30 | DP | |
| Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met Xr, Takeda Pharms Usa | |||
| 7785627 | 2026-07-31 | DP | |
| 7959946 | 2026-07-31 | DP | |
| 8470368 | 2023-09-19 | DP | |
| 8668931 | 2023-09-19 | DP | |
| 9060941 | 2023-09-19 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD05: Metformin and pioglitazone
— A10BD06: Glimepiride and pioglitazone
— A10BD09: Pioglitazone and alogliptin
— A10BD12: Pioglitazone and sitagliptin
— A10BG: Thiazolidinediones, blood glucose lowering drugs
— A10BG03: Pioglitazone
HCPCS
No data
Clinical
Clinical Trials
536 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 7 | 34 | 84 | 67 | 48 | 231 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 7 | 16 | 12 | 1 | 36 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | 3 | 8 | 5 | 10 | 5 | 29 |
| Healthy volunteers/patients | — | — | — | 24 | 1 | — | 1 | 1 | 27 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 4 | 1 | 12 | — | 18 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 3 | 4 | 1 | 6 | 4 | 17 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 2 | 1 | 3 | 6 | 16 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 4 | 1 | — | 4 | 2 | 11 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 1 | 2 | 4 | 8 |
| Coronary artery disease | D003324 | — | I25.1 | — | 2 | 2 | 4 | — | 7 |
Show 44 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 3 | 1 | — | — | 4 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | — | 1 | — | 1 | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 2 | 1 | — | — | 4 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | 1 | 1 | — | 1 | 3 |
| Kidney transplantation | D016030 | — | — | — | 1 | 1 | — | 1 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 2 | — | — | 3 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | 1 | — | 1 | 2 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Risk reduction behavior | D040242 | — | — | — | — | 1 | — | — | 1 |
| Coronary restenosis | D023903 | EFO_0004224 | — | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 5 | — | — | 1 | 6 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 5 | — | — | — | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 3 | — | — | — | 3 |
| Oral leukoplakia | D007972 | — | K13.21 | — | 3 | — | — | — | 3 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 1 | 2 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | 1 | — | — | — | 2 |
| Squamous cell carcinoma | D002294 | — | — | — | 2 | — | — | — | 2 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 2 | — | — | — | 2 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | 2 | — | — | — | 2 |
Show 39 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | 2 | 3 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Infertility | D007246 | HP_0000789 | — | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | — | — | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | — | — | — | 1 |
| Female infertility | D007247 | EFO_0008560 | N97 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | — | — | — | — | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | 1 | — | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 2 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Ketosis | D007662 | HP_0002919 | R82.4 | — | — | — | — | 1 | 1 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | — | 1 | 1 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
| Peritoneal dialysis | D010530 | — | — | — | — | — | — | 1 | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | — | — | 1 | 1 |
| Hypogonadism | D007006 | HP_0000044 | E23.0 | — | — | — | — | 1 | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pioglitazone |
| INN | pioglitazone |
| Description | Pioglitazone is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines. |
| Classification | Small molecule |
| Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1 |
Identifiers
| PDB | — |
| CAS-ID | 111025-46-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL595 |
| ChEBI ID | 8228 |
| PubChem CID | 4829 |
| DrugBank | DB01132 |
| UNII ID | X4OV71U42S (ChemIDplus, GSRS) |
Target
Agency Approved
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Alternate
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Pioglitazone
+
Glimepiride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pioglitazone
+
Metformin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pioglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,975 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alogliptin and pioglitazone, Duetact, Oseni, Pioglitazone and glimepiride, Pioglitazone hydrochloride and glimepiride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,065 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use